Posted 12 November 2021 | By Kari Oakes
What do you think? Wed be happy to hear your feedback at news@raps.org.
The House Committee on Oversight and Reform informed the consulting firm McKinsey late last week of the committees investigation into McKinseys consulting services on behalf of industries causing public harm, the companys conflicts of interest, and its apparent failure to monitor and prevent harmful practices. McKinsey, says the letter, has advised Oxycontin maker Purdue Pharma as well as opioid distributors and retail pharmacies, while at the same time consulting for the US Food and Drug Administration (FDA) to the tune of over $140 million, creating the potential for significant conflicts of interest.To address the deemed final order and proposed order for over-the-counter (OTC) sunscreen drugs, FDA plans a 15 December webinar that will give an overview of the regulatory history for sunscreens. Earlier that same day, the agency will offer a webinar giving a broad overview of FDAs OTC monograph reform, highlighting deemed final orders and changes in OTC drug review after the Coronavirus Aid, Relief, and Economic Security Act (CARES Act).FDAs recent Coronavirus update details the agencys new emergency use authorization for the iHealth COVID-19 Antigen Rapid Test for at-home use, and the issuance of the first 510(k) for the BioFire COVID-19 Test 2. The agency also authorized the release of two more batches of Johnson & Johnsons COVID-19 vaccine manufactured at the troubled Emergent facility in Baltimore, Maryland. While the FDA is not yet ready to include the Emergent BioSolutions plant in the Janssen EUA as an authorized manufacturing facility, the agency continues to work through issues on this matter with Janssen and Emergent BioSolutions management, wrote FDA.FDAs acting chief, Janet Woodcock, gave opening remarks at the Association for Accessible Medicines 2021 GRx+Biosims Conference this week. While our agency does not play a direct role in drug pricing, we can by encouraging development of lower-cost generic and biosimilar products support competition in the health care market, said Woodcock. Read more coverage of the conference here.Enforcement cornerWe saw two noteworthy warning letters this week. The first went to Infusion Options, whose Brooklyn warehouse had sterility problems including drugs stored on the floor of a bathroom that appeared to be actively used as such, along with labeling and current good manufacturing practices (CGMP) issues. For now, the firm has ceased operations. A contract testing laboratory also received a warning about its lax control over data acquisition systems, lack of an adequate audit trail, and lack of quality unit oversight for electronic lab monitoring operations.CBERs Office of Compliance and Biologics Quality issued another untitled letter concerning unauthorized stem cell products this week. The recipients, owners of Colts Neck Stem Cells and Regenerative Medicine, drew FDAs ire for advertising claims on its company Facebook page such as KIDNEY DISEASE STEM CELL MIRACULOUS SUCCESS! and her chronic wound got better in 10 days after injecting stem cells...she avoided amputatio[n]. This is the 17th such letter issued this year; in April, CBER head Peter Marks said that the agencys period of enforcement discretion against such infractions is coming to an end.Other device newsFDAs Center for Devices and Radiologic Health (CDRH) released a summary of the 2 November meeting of the Circulatory System Devices Panel of the Medical Devices Advisory Committee. The panel considered the problem of Type III endoleaks with Endologix AFX endovascular graft systems. According to the summary, the panel believes that more clinical data are needed for full evaluation of the entire AFX family of devices. The sponsors current mitigation strategies were deemed inadequate to address the clinically meaningful risk of Type III endoleaks, though the panel stopped short of recommending that the device be withdrawn.In other device news, CDRH announced a class I recall for custom convenience kits marketed by Windstone Medical Packaging, because of a plunger defect in the Cardinal Health saline-filled syringe included in the kits. The agency also announced that it has updated its template for sponsors seeking an EUA for at-home COVID-19 tests.From the JournalsThe behavior of the influenza virus has lessons to teach us about how we address vaccines against SARS-CoV-2, said the University of Michigans Arnold Monto in a New England Journal of Medicine editorial this week. The successful publicprivate collaboration in selecting influenza strains offers a model for dealing with such issues, wrote Monto, who has been the acting chair of FDAs vaccines advisory committee through the COVID-19 pandemic. He added, SARS-CoV-2 vaccines will be used globally, and the strain or strains contained in future vaccines will need to be chosen globally, in consultation with the manufacturers.About 10% of all recent generic applications requested competitive generic therapy (CGT) designation, according to a JAMA research letter from Harinder Singh Chahal, of FDAs Office of the Commissioner, and other FDA coauthors. A sizable fraction of generic applicants requested CGT designation, and many drugs approved with CGT exclusivity eligibility marketed within 2.5 days after approval, which can benefit the health care system and patients, according to the FDA officials.A pair of studies led by Yales Joshua Wallach appeared this week in JAMA Network Open, examining FDAs accelerated approvals from 2009-2018. Wallach and his colleagues found that real-world evidence could not easily be substituted for confirmatory postapproval clinical trials. These postapproval trials, though, dont really last much longer than pivotal trials, calling into question one justification for allowing early approval based on surrogate endpoints. Our coverage of both studies is here.What were reading and watchingThe Biden administration announced this week that it plans to invest an additional $650 million into expanding access to rapid diagnostic tests for COVID-19. The funds will be used to ramp up US domestic manufacturing capacity, by purchasing raw materials and finished tests, according to the announcement. The US Department of Health and Human Services is taking other actions to bring costs down and boost availability of rapid, over-the-counter COVID-19 tests.The Duke-Margolis Center for Health Policy held its 13th annual Sentinel Initiative public workshop on 8 and 9 November. Topics addressed by FDA officials and other participants included how to improve causal inference for generation of real-world evidence, an update on work thats being done to build robust evidence generation systems, and how Sentinel and FDAs Biologics and Effectiveness Safety (BEST) systems have been used for near-real-time data gathering during the pandemic. The full workshop is now viewable on the Duke-Margolis centers website.
The rest is here:
This Week at FDA: CDRH and Endologix leaks, OTC monograph reform, and more - Regulatory Focus
- The ISSCR announces 2024 election results - EurekAlert - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Charles River Extends Gene Therapy Alliance with NUS Medicine - Contract Pharma - March 22nd, 2024
- Exciting opportunities in stem cell technology and regenerative biology in Indian healthcare industry - Express Healthcare - March 22nd, 2024
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine - Yahoo Finance - March 22nd, 2024
- Opinion: The revolutionary sickle cell therapies - MSN - March 22nd, 2024
- 10 Years of Kansas Regenerative Medicine Center - KSAL - March 22nd, 2024
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership - Diagnostic and Interventional Cardiology - March 17th, 2024
- Cynata Therapeutics' breakthrough in regenerative medicine - Finance News Network - March 17th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - GlobeNewswire - March 17th, 2024
- Novel 3D stem cell therapy to treat critical limb ischaemia - Drug Target Review - March 15th, 2024
- Breaking Boundaries: Pharmicell's Bold Vision for Healthcare Transformation and Monumental Growth - The Worldfolio - March 15th, 2024
- CuSTOM Organoid Research Evolving From Tool to Treatment - Research Horizons - Research Horizons - March 15th, 2024
- BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene Therapy for Remuscularization of Heart - Cath Lab Digest - March 15th, 2024
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine ... - Business Wire - March 13th, 2024
- Iron restriction keeps blood stem cells young, researchers find - Phys.org - March 13th, 2024
- Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues - March 9th, 2024
- Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology - March 7th, 2024
- Stem Cell Therapy Market (CAGR) of 31.1%, Future of Market Size Emerging Technologies and their Impact on ... - Taiwan News - March 7th, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 6th, 2024
- Advancing stem cell therapy: The regulatory process to get to clinical trials - The Economic Times - March 6th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 6th, 2024
- 'Mini organs' are grown from human stem cells taken during the late stages of pregnancy for the first time - m - Daily Mail - March 6th, 2024
- Stem cell transplant cures man of HIV and leukemia, one of five to achieve full remission - Fox 28 - March 3rd, 2024
- Stem Cell Therapy Market to Boost USD 137.5 Billion by 2034 and Projected to grow at 32.10% CAGR with increasing ... - Yahoo Finance - March 1st, 2024
- Studies expand use of stem cell therapies - WPLG Local 10 - March 1st, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Unlocking the Potential of Stem Cells: The Medical Revolution of the Century - EIN News - February 27th, 2024
- Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine ... - Yahoo Finance - February 27th, 2024
- Say Her Name - Henrietta Lacks, The Real Mother Of Stem - Her Campus - February 27th, 2024
- California Man Free of HIV And Cancer in Astonishing Medical Recovery - ScienceAlert - February 25th, 2024
- $93 million for research into improved health for children, young people and the aged, medical devices, mental health ... - Department of Health - February 25th, 2024
- Stem Cells in Regenerative Medicine - PMC - National Center for ... - February 24th, 2024
- The Promise and Reality of Stem Cell Therapy: What You Need to Know - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy: A Beacon of Hope for Patients with Untreatable Conditions - Corporate Wellness Magazine - February 22nd, 2024
- Leading Experts in Stem Cell Therapy: A Global Overview - Corporate Wellness Magazine - February 22nd, 2024
- Can Stem Cells Help Reverse the Effects of Aging? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy for Cancer: Hope on the Horizon? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cells and Autism: A Closer Look at Innovative Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Regrowth and Restoration: The Science Behind Stem Cell Therapy for Hair - Corporate Wellness Magazine - February 22nd, 2024
- Brain Recovery: The Role of Stem Cells in Stroke and Cerebral Palsy Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Turning Back the Clock: The Science of Stem Cells in Anti-Aging - Corporate Wellness Magazine - February 22nd, 2024
- Insights into cellular therapies for cancer treatment - Drug Target Review - February 22nd, 2024
- The Role of Stem Cells in Rheumatoid Arthritis Recovery - Corporate Wellness Magazine - February 22nd, 2024
- Dr Ernesto Romeros vision transforms immunotherapy regenerative medicine into a global leader in stem cell treatment - Khaleej Times - February 22nd, 2024
- World-Renowned Doctors Leading the Way in Stem Cell Research and Treatment - Medical Tourism Magazine - February 20th, 2024
- Choosing the Best: A Guide to America's Premier Stem Cell Therapy Providers - Medical Tourism Magazine - February 20th, 2024
- Navigating Through the Possibilities of Stem Cell Treatment for Eye Disorders - Medical Tourism Magazine - February 20th, 2024
- Global Leaders in Stem Cell Therapy: Where Excellence Meets Innovation - Medical Tourism Magazine - February 20th, 2024
- Excellence in Stem Cell Treatment: How the US is Pioneering Global Healthcare Solutions - Medical Tourism Magazine - February 20th, 2024
- Clarifying Memory Loss Treatments: The Role of Stem Cells - Medical Tourism Magazine - February 20th, 2024
- Battling Inflammation: Stem Cell Therapy for Rheumatoid Arthritis - Medical Tourism Magazine - February 20th, 2024
- Digestive Health and Stem Cells: Treating Ulcerative Colitis and Crohn's Disease - Medical Tourism Magazine - February 20th, 2024
- Top Stem Cell Clinics in the USA: Pioneering Treatments for Chronic Conditions - Medical Tourism Magazine - February 20th, 2024
- Stem Cells and Autism: Understanding the Potential for Innovative Treatments - Medical Tourism Magazine - February 20th, 2024
- Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse - University of Birmingham - February 20th, 2024
- City of Hope Achieves Ground Breaking Treatment for Blood Cancer and HIV - Medriva - February 18th, 2024
- Regenerative Medicine Market Size to Worth USD 95 Billion by 2032 - InvestorsObserver - February 18th, 2024
- North America Organoids Market Projected to Reach US$ 5.35 Billion by 2030, Riding on a CAGR of 21.5% - GlobeNewswire - February 18th, 2024
- Chinese team tests lung treatment that may be first to reverse COPD damage - South China Morning Post - February 15th, 2024
- Why leukemic stem cells not harmed by chemotherapy begin to grow and produce AML cells after treatment - Medical Xpress - February 15th, 2024
- Regenerative Medicine Market is Expected to Reach $49.0 Billion | MarketsandMarkets - Yahoo Finance - February 15th, 2024
- Study finds interleukin-24 enhances CAR-T cell therapy's effectiveness against cancer stem cells - News-Medical.Net - February 15th, 2024
- Oldest Patient 'Cured' of HIV Still in Remission 5 Years After Transplant for AML - Medpage Today - February 15th, 2024
- Drug used for cocaine addiction may pave way for new treatment of advanced colon cancer - EurekAlert - February 15th, 2024
- Hematopoietic Stem Cells and Their Role in Development and Disease Therapy - The Scientist - February 15th, 2024
- Biomedical Researcher Seeks to Improve Outcomes in Stem Cell Treatments - University of Arkansas Newswire - February 13th, 2024
- Top 3 grants in regenerative medicine: January 2024 - RegMedNet - February 13th, 2024
- Scalise returning to Washington next week with cancer in complete remission - The Hill - February 13th, 2024
- Unlocking the power of stem cell therapy - Drug Target Review - February 9th, 2024
- Digging into the Dangers of Gene Therapy - The Medicine Maker - February 7th, 2024
- Treating and preventing abnormal heart beats with stem cell muscle grafts - Medical Xpress - February 7th, 2024
- Regeneration of the Retina Using Pluripotent Stem Cells: A Comprehensive Review - Cureus - February 3rd, 2024
- I thought I'll give it a chance - Liam Harrison reveals his thought process in getting crucial stem cell treatment - Sportskeeda - February 3rd, 2024
- Jennifer J. Raab named President and CEO of The New York Stem Cell Foundation - EurekAlert - February 3rd, 2024
- High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary ... - The Lancet - January 31st, 2024
- Houston regenerative medicine company to IPO, move toward more human trials - InnovationMap - January 31st, 2024
- New study on promising stem cell-based therapy for Crohn's disease - Medical Xpress - January 31st, 2024
- Exploring pharmacological, non-pharmacological, and stem cell therapies for treatment of autism spectrum disorders - News-Medical.Net - January 29th, 2024
- Stem cell study shows how gene activity modulates the amount of immune cell production in mice - Medical Xpress - January 26th, 2024
Recent Comments